In this anti-PD-1-resistant model, a combination of agonistic anti-CD40 together with an anti-PD-1 immune checkpoint blockade induced a good immune response, leading to tumor control through the recruitment of newly activated CD8+ T cells in the tumor and a modification of the tumor microenvironment [12]. Here, PDCD1 is linked to neoplasm.